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Abstract
Background: Because limited data are available, the present study investigated 2-year major 
clinical outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II 
type 1 receptor blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) 
and prediabetes after successful implantation of newer-generation drug-eluting stents (DESs).
Methods: Overall, 2932 patients with AMI and prediabetes were classified into two groups 
— the ACEIs group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the 
occurrence of patient-oriented composite outcome (POCO), defined as all-cause death, 
recurrent myocardial infarction (Re-MI), or any repeat revascularization. The secondary 
endpoint was definite or probable stent thrombosis (ST). 
Results: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% 
confidence interval [CI]: 0.740–1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 
0.803–2.419; p = 0.238), Re-MI (aHR: 1.210; 95% CI: 0.626–2.340; p = 0.570), any repeat 
revascularization (aHR: 1.150; 95% CI: 0.713–1.855; p = 0.568), and ST (aHR: 1.736; 95% 
CI: 0.445–6.766; p = 0.427) were similar between the groups. These results were confirmed 
after propensity score-adjusted analysis. 
Conclusions: In this study, patients with AMI and prediabetes who received ACEIs or ARBs 
showed comparable clinical outcomes during the 2-year follow-up period. 
Key words: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, 
myocardial infarction, prediabetes, outcomes
INTRODUCTION
Higher fasting glucose levels on admission are related to worse clinical outcomes 
regardless of the presence or absence of diabetes [1, 2]. Huang et al. [3] reported that 
prediabetes was associated with an increased risk of composite cardiovascular disease, 
coronary heart disease, and all-cause mortality compared with normoglycemia. Although the 
exact underlying mechanism between prediabetes and increased mortality is not well known, 
a higher prevalence of cardiac autonomic dysfunction in prediabetes was suggested [4]. 
Impaired endothelial function and increased oxidative stress at the vessel wall led to 
activation of platelets, inflammation, and thrombosis in patients with undiagnosed diabetes or
prediabetes [5]. Moreover, hyperglycemia has been linked to an increase in plasma renin 
activity with renin–angiotensin system (RAS) activation, which is known to impair insulin 
signaling [6].
Renin–angiotensin system inhibitors (RASIs) have been shown to have diverse 
beneficial effects on cardiovascular outcomes through the enhancement of endothelial 
function, cardiovascular remodeling, and progression of atherosclerosis [7, 8], and have 
positive roles in delaying or preventing the onset of diabetes mellitus (DM) [9]. The current 
guidelines recommend that angiotensin-converting enzyme inhibitors (ACEIs) should be used
as the first-line choice of RASIs after acute myocardial infarction (AMI) and angiotensin II 
type 1 receptor blockers (ARBs) should be considered in patients who are intolerant to ACEIs
therapy [10–13]. However, the relative superiority of ACEIs and ARBs in AMI patients with 
regards to long-term clinical outcomes is still debatable [14, 15]. Choi et al. [16] reported that
ACEIs or ARBs have similar effects on reducing death, recurrent myocardial infarction (Re-
MI), revascularization, and major adverse cardiac events in ST-segment elevation myocardial 
infarction (STEMI) patients with diabetes. More recently, one meta-analysis [17] suggested 
that ACEIs was preferred than ARBs in patients with hypertension and type 2 diabetes 
(T2DM). However, very limited data are available comparing the long-term major clinical 
outcomes between ACEIs and ARBs therapy in AMI patients with prediabetes. Hence, we 
investigated the 2-year clinical outcomes following ACEIs and ARBs therapy in AMI patients
with prediabetes after new-generation drug-eluting stents (DESs) implantation.
METHODS
Study population
This study enrolled patients from the Korea AMI Registry (KAMIR) [18]. A total of 
21,343 patients with AMI who underwent successful percutaneous coronary intervention 
(PCI) with new-generation DESs from November 2005 to June 2015 were evaluated in this 
retrospective cohort study. Among them, patients with incomplete laboratory results (n = 
8314, 39.0%), those who were lost to follow-up (n = 1067, 5%), those with normoglycemia 
(n = 3080, 14.4%), those with DM (n = 5173, 24.2%), those who were not prescribed ACEIs 
or ARBs (n = 765, 3.6%), and those who were concomitantly using ACEIs and ARBs (n = 12,
0.1%) were excluded. Finally, a total of 2932 patients with AMI who underwent successful 
implantation of newer-generation DESs and who had been prescribed ACEs or ARBs were 
considered for inclusion. These patients were divided into two groups — the ACEIs group (n 
= 2059, 70.2%) and the ARBs group (n = 873, 29.8%) (Fig. 1). This study protocol was 
approved by the ethics committee at each participating center and the Chonnam National 
University Hospital Institutional Review Board ethics committee (CNUH-2011-172) 
according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided 
written informed consent prior to enrollment, and they completed a 2-year clinical follow-up 
through face-to-face interviews, phone calls, and chart reviews. Additionally, all clinical 
events were evaluated by an independent event adjudicating committee. The process off event
adjudicating is described in the previous publication by KAMIR investigators [18].
Percutaneous coronary intervention procedures and medical treatment
Percutaneous coronary intervention was performed using the standard technique [19].
Before PCI, all patients received loading doses of acetylsalicylic acid (ASA; 200–300 mg) 
and other anti-platelet agents, including clopidogrel, ticagrelor, or prasugrel. After the index 
PCI, dual antiplatelet therapy (DAPT; a combination of acetylsalicylic acid 100 mg/day with 
clopidogrel 75 mg/day or ticagrelor 90 mg twice daily or prasugrel 5–10 mg/day) was 
recommended for at least 1 year. The use of triple antiplatelet therapy (cilostazol 100 mg 
twice daily added to DAPT) was left to the discretion of the individual operators. The kinds 
and doses of ACEIs or ARBs were as follows; 12.5–75 mg of captopril, 1.25–10 mg of 
ramipril, 2.5–10 mg of perindopril, 1.25–5 mg of cilazapril, 5–10 mg of imidapril, 7.5–30 mg
of moexipril, 2.5–10 mg of enalapril, 5–10 mg of lisinopril, 10 mg of fosinopril, 3.75–7.5 mg 
of zofenopril, 25–100 mg of losartan, 150–300 mg of irbesartan, 40–160 mg of valsartan, 40–
80 mg of telmisartan, 10–20 mg of olmesartan, 4–32 mg of candesartan, 600 mg of 
eprosartan, and 15–60 mg of fimasartan per day.
Study definitions and clinical outcomes
Glycemic status of the enrolled patients was estimated based on medical history and 
glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels at the index 
hospitalization. According to the definition of the American Diabetes Association [20], 
prediabetes was defined as an HbA1c of 5.7–6.4% and an FPG of 100–125 mg/dL (5.6–6.9 
mmol/L). The definitions of STEMI and non-STEMI (NSTEMI) were defined by the current 
guidelines [11, 13]. An early invasive treatment strategy of the patients with NSTEMI was 
defined as PCI within 24 hours after admission [13]. A successful PCI was defined as a 
residual stenosis less than 30% and thrombolysis in myocardial infarction grade 3 flow for 
the infarct-related artery (IRA) after the procedure. The primary endpoint of this study was 
the occurrence of patient-oriented composite outcomes (POCO) composed of all-cause death,
Re-MI, or any coronary repeat revascularization [21]. The secondary endpoint was definite or
probable stent thrombosis (ST) during the 2-year follow-up period. All-cause death was 
classified as CD or non-CD. The definitions of any repeat revascularization, Re-MI were 
previously reported [22]. The cumulative incidence of ST was defined by the current 
consensus [23].
Statistical analysis
Categorical data are reported as numbers and percentages, and were compared using 
the χ2 or Fisher’s exact test as appropriate. Continuous variables are expressed as mean ± 
standard deviation and were compared using Student’s t-test. Any variables with a p value of 
< 0.001 in the univariate analysis and conventional risk factors of poor outcomes in the AMI 
population were considered potential confounding factors, and were entered into the 
multivariate analysis. This included age, left ventricular ejection fraction (LVEF), STEMI, 
NSTEMI, hypertension, current smokers, clopidogrel, ticagrelor, beta-blockers (BBs), 
American College of Cardiology/American Heart Association (ACC/AHA) type B2 and C 
lesion, one-vessel disease, and stent diameter. Various clinical outcomes were estimated using
the Kaplan–Meier curve analysis, and differences between the groups were compared using 
the log-rank test. For all analyses, two-sided p values < 0.05 were considered statistically 
significant. In addition, to adjust for any potential confounders, a propensity-score (PS) 
adjusted analysis was performed using a logistic regression model (Suppl. Material 1). All 
available variables listed in Table 1 that could be of potential relevance were tested. The PS 
was estimated using a C-statistic for the logistic regression model and the PS for the two 
groups was 0.718. Proportional hazard models were used to assess the hazard ratio (HR) of 
the ARBs group compared with the ACEIs group adjusted PS. All statistical analyses were 
performed using SPSS software, version 20 (IBM; Armonk, NY, USA).
RESULTS
Baseline characteristics
Table 1 shows the baseline characteristics of the study population. The mean age of 
patients in the ARBs group was greater than the mean age of the patients in the ACEIs group 
(64.4 ± 12.2 years vs. 62.2 ± 12.4 years; p < 0.001). The mean value of LVEF (54.6 ± 10.8% 
vs. 52.4 ± 10.5%; p < 0.001) was higher in the ARBs group. The number of patients with 
STEMI was higher in the ACEIs group than in the ARBs group. In contrast, the number of 
NSTEMI patients was higher in the ARBs group. The number of current smokers, blood 
levels of peak level of creatine kinase myocardial band and total cholesterol, prescription 
rates of clopidogrel and BBs; number of left anterior descending coronary artery as an IRA 
and ACC/AHA type C lesion, and the mean diameter of deployed stents were higher in the 
ACEIs group than in the ARBs group. Compared with the ACEIs group, the ARBs group had 
higher number of patients with cardiopulmonary resuscitation (CPR) on admission and 
hypertension, a previous history of heart disease (MI, PCI, and coronary artery bypass graft), 
a higher level of N-terminal pro-B-type natriuretic peptide, a higher incidence of left main 
coronary artery as an IRA (2.2% vs. 0.8%; p = 0.002) and a treated vessel (3.8% vs. 1.9%; p 
= 0.003), more ACC/AHA type B2 lesions, and a higher incidence of one-vessel disease. 
However, the number of primary PCIs performed; PCIs performed within 24 hours of 
admission; cardiogenic shock; the kinds of stents deployed; and the use of intravascular 
ultrasound; optical coherence tomography and fractional flow reserve was similar between 
the two groups.
Clinical outcomes 
Table 2 and Figure 2 show the cumulative incidences of major clinical outcomes. 
Before adjustment, the cumulative incidence of CD was significantly higher in the ARB 
group than in the ACE group (2.3% vs. 1.2%; p = 0.030; Table 2). After adjustment, both 
groups had similar cumulative incidences of POCO (adjusted HR [aHR]: 1.020; 95% 
confidence interval [CI]: 0.740–1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 
0.803–2.419; p = 0.238), CD (aHR: 1.791; 95% CI: 0.952–3.371; p = 0.071), Re-MI (aHR: 
1.210; 95% CI: 0.626–2.340; p = 0.570), death or MI (aHR: 1.143; 95% CI: 0.751–1.741; p =
0.533), any repeat revascularization (aHR: 1.150; 95% CI: 0.713–1.855; p = 0.568), and ST 
(aHR: 1.736; 95% CI: 0.445–6.766; p = 0.427). Further, after PS-adjusted analysis, the 
cumulative incidences of POCO (aHR: 1.105; 95% CI: 0.745–1.641; p = 0.619), all-cause 
death (aHR: 1.025; 95% CI: 0.528–1.989; p = 0.941), CD (aHR: 1.397; 95% CI: 0.642–
3.042; p = 0.400), Re-MI (aHR: 1.290; 95% CI: 0.544–3.062; p = 0.563), death or MI (aHR: 
1.117; 95% CI: 0.661–1.889; p = 0.680), any repeat revascularization (aHR: 1.140; 95% CI: 
0.630–2.063; p = 0.666), and ST (aHR: 3.003; 95% CI: 0.606–14.88; p = 0.178) were also 
similar between the groups. Table 3 shows the independent predictors of POCO at 2 years. 
Old age (≥ 65 years, aHR: 1.396; 95% CI: 1.015–1.919; p = 0.040), CPR on admission (aHR:
2.418; 95% CI: 1.414–4.137; p = 0.001), and multivessel disease (aHR: 1.656; 95% CI: 
1.226–2.238; p = 0.001) were meaningful independent predictors for POCO. The results of 
subgroup analysis using Cox regression model in the total study population (Fig. 3) showed 
that all parameters including age, sex, STEMI, CPR on admission, hypertension, BBs, 
ACC/AHA type B2/C lesions, stent diameter, stent length, and multivessel disease were 
comparable between the two groups.
DISCUSSION
The main findings of this study are: (1) the cumulative incidences of POCO, all-
cause death, Re-MI, any repeat revascularization, and ST were not significantly different 
between the ACEI and ARB groups; and (2) old age, cardiopulmonary resuscitation on 
admission, and multivessel disease were independent predictors of POCO.
According to current guidelines, RASIs are recommended to improve cardiovascular 
outcomes in patients with AMI regardless of the presence or absence of diabetes and 
prediabetes, inevitably [10–13]. Therefore, it was thought that patients with AMI and 
prediabetes who had been prescribed ACEIs or ARBs following implantation of newer-
generation DESs were considered for inclusion and we decided to determine the relative 
superiority of ACEIs and ARBs during a long-term follow-up period in this study. Diverse 
and complex potential mechanisms underlying the protective effects of RASIs have been 
reported. Through their vasodilation capacity, RASIs can improve muscular blood flow and 
may promote insulin secretion by enhancing pancreatic blood flow [24]. In addition, RASIs 
can decrease sympathetic activity, improve cellular insulin action and insulin secretion by 
preserving cellular potassium and magnesium pools, and reduce the incidence of diabetes 
through direct inhibition of angiotensin and/or enhancement of bradykinin [24]. Further, as 
some RASIs have thiazolidinedione-like activity, which induces peroxisome proliferator-
activated receptor-γ activity, they may improve insulin sensitivity [24].
With regard to diabetes, data regarding the beneficial role of ACEIs or ARBs in 
patients with diabetes are controversial or uncertain [25–27]. In the DIABHYCAR (non-
insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular 
events, and ramipril) study [27], administration of low-dose (1.25 mg) ramipril once daily did
not show any effect on cardiovascular and renal outcomes in patients with type 2 diabetes and
albuminuria. Haller at al. [26] suggested that olmesartan was associated with a higher rate of 
fatal cardiovascular events among patients with pre-existing coronary heart disease. A meta-
analysis [25] demonstrated that compared with controls, ACEIs reduced the risk of all-cause 
death and cardiovascular death by 13% and 17%, respectively, in patients with DM during the
1-year follow-up period. However, ARBs did not significantly affect all-cause death and 
cardiovascular death in this meta-analysis. In patients with DM and albuminuria, Wang et al. 
[28] showed that ARBs reduced risks of end stage renal disease and doubling of serum 
creatinine level. ACEIs and ARBs failed to reduce all-cause mortality and cardiovascular 
events. With respect to renoprotective effects, ARBs may be preferred for diabetic patients 
with albuminuria. Lv et al. [17] suggested that treatment with ACEIs showed a significant 
cardiovascular protection for all-cause mortality, cardiovascular death, and major 
cardiovascular events, whereas ARBs had no benefits on these outcomes except myocardial 
infarction. 
With regard to prediabetes, limited data are available regarding the comparative 
long-term effects of follow-up with ACEIs and ARBs [29-31]. Zidek et al. [29] suggested that
ramipril was preferable to diuretics for the management of hypertension in prediabetes, 
considering the prevalence of new-onset diabetes. Min et al. [30] demonstrated that 
angiotensin II played an important role in the development of albuminuria in patients with 
impaired glucose metabolism. In an animal study, Zhang et al. [31] showed that angiotensin 
II type 1 receptor-mediated coronary vasoconstriction is augmented in prediabetes, which 
may contribute to impaired coronary blood flow. This suggests that RASIs may be involved 
in one of the major determinants of prediabetes. Although both ACEIs and ARBs limit the 
effects of angiotensin II, their mechanisms of action are not identical [32, 33]. Compared with
ACEIs, ARBs increase circulating angiotensin II levels through unwanted stimulation of the 
angiotensin II type 2 (AT2) receptor. Increased number of AT2 receptor is an important cause 
of plaque instability and thrombus formation in patients with coronary artery disease [32]. 
Despite these limitations of ARBs, the cumulative incidence of primary and secondary 
endpoints was similar between the two groups in this study. Further, these results were 
confirmed after PSM analysis. 
According to available research, there are no studies that can be used to directly 
compare the results of the present study. Therefore, determining a meaningful value of this 
study compared to those of other studies and speculating about the main cause of the results 
of this study compared to those of other studies are challenging. Previous studies that 
compared the clinical outcomes between ACEIs and ARBs were not performed in the era of 
newer-generation DESs [14, 32, 34], concomitantly used newer-generation and non-newer-
generation DESs [25], or also included patients with other conditions which were not 
confined to AMI [27, 29]. Yang et al. [35] reported that ARBs were as beneficial as ACEIs in 
STEMI patients with preserved LVEF after PCI. Similar to the Yang et al. report [35], the 
study population of this study was composed of patients who had relatively well-preserved 
LVEFs (53.1 ± 10.6%, Table 1) and the number of STEMI patients was more than 50%. 
Therefore, these baseline characteristics may be related with the similar cumulative 
incidences of primary and secondary endpoints between ACEIs and ARBs. In a recent large 
retrospective study with more than half a million patients (from the United States, Germany, 
and South Korea) has suggested that there is no advantage from one or another in 
cardiovascular endpoints, but ARBs are associated with a better safety profile [36]. In their 
study [36], the primary outcomes of AMI (HR: 1.11 for ACEs vs. ARBs [95% CI: 0.95–
1.32]), heart failure (HR: 1.03; 95% CI: 0.87–1.24), stroke (HR: 1.07; 95% CI: 0.91–1.27), or
composite cardiovascular events (HR: 1.06; 95% CI: 0.90–1.25) were not statistically 
different between the ACEIs and ARBs groups. Regarding secondary and safety outcomes, 
patients on ARBs had significantly lower risk of angioedema, cough, pancreatitis, and 
gastrointestinal bleeding. Therefore, these findings support preferentially prescribing ARBs 
over ACEIs when initiating treatment for hypertension.
In this study, prediabetes was defined as an HbA1c of 5.7–6.4% and an FPG of 100–
125 mg/dL (5.6–6.9 mmol/L) [20]. Moreover, the International Diabetes Federation has 
suggested that the diagnosis of prediabetes be made based on the HbA1c since it can be 
measured under a non-fasting condition [37]. However, because there are some 
disagreements between oral glucose tolerance test (OGTT) and HbA1c, OGTT is considered 
more sensitive than the HbA1c test for defining prediabetes [38]. Regarding some previous 
report [39] that showed positive correlation between glycated hemoglobin and CD or non-
CD, HbA1c can be used as alternative diagnostic tool for such assessments in patients with 
AMI [34]. 
This study was conducted in the era of contemporary newer-generation DESs, and 
multivariable analysis and PSM were performed to strengthen our results. Our study 
demonstrates that ACEIs and ARBs had comparable clinical outcomes in terms of POCO, all-
cause death, Re-MI, any revascularization, and ST during a 2-year follow-up period. In 
addition, similar results were observed after subgroup analysis. Thus, we speculate that our 
study may provide a meaningful message to interventional cardiologists who perform PCI 
with newer-generation DESs in patients with AMI and prediabetes regarding the use of 
ACEIs or ARBs.
Limitations of the study
This study has several limitations. First, because this study was conducted based on 
the level of HbA1c, the results of this study can be altered based on OGTT. Second, because 
this study was based on discharge medications, we did not precisely reflect drug compliance 
and drug-related non-cardiovascular effects of the enrolled patients during the follow-up 
period. Third, we could not provide correct information concerning the degree of glycemic 
control of the enrolled patients during the follow-up period due to deficit of detailed 
information of the KAMIR. Fourth, the selection of ACEIs or ARBs after PCI was left to the 
discretion of the physicians. This may act as an important bias in this study. Fifth, although 
multivariable and PS-adjusted analysis were performed to strengthen our results, the patients 
who were not matched at enrollment or other many clinical variables — both known and 
unknown — could lead to bias not accounted for by PS-adjusted analysis.
CONCLUSIONS
To conclude, in the era of contemporary newer-generation DESs, patients with AMI 
and prediabetes who underwent successful PCI and who received ACEIs or ARBs showed 
comparable clinical outcomes during the 2-year follow-up period. However, the study results 
should be re-evaluated in a large-scale, randomized controlled study.
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Figure 1. Flow chart. 
Figure 2. The Kaplan-Meier Analysis for patient-oriented composite outcomes (POCO; A), 
all-cause death (B), cardiac death (C), recurrent myocardial infarction (Re-MI; D), death or 
myocardial infarction (MI; E), any repeat revascularization (F), and stent thrombosis (G) at 2
years.
Table 1. Baseline clinical, laboratory, angiographic, and procedural characteristics. 
Variables Total (n = 2932) ACEIs (n = 2059) ARBs (n = 873) P SD
Age [years] 62.9 ± 12.4 62.2 ± 12.4 64.4 ± 12.2 < 0.001 –1.79
Men 2243 (76.5%) 1609 (78.1%) 634 (72.6%) 0.001 1.71
LVEF [%] 53.1 ± 10.6 52.4 ± 10.5 54.6 ± 10.8 < 0.001 –2.07
BMI [kg/m2] 24.3 ± 3.2 24.3 ± 3.1 24.2 ±3.2 0.575 0.32
SBP [mmHg] 131.1 ± 27.3 131.0 ± 27.2 131.3 ± 27.5  0.798 –0.10
DBP [mmHg] 79.8 ± 16.2 79.6 ± 16.3 80.3 ± 16.2 0.304 –0.43
STEMI 1759 (60%) 1281 (62.2%) 478 (54.8%) < 0.001 2.01
Primary PCI 1702/1759 (96.8%) 1237/1281 (96.6%) 465/478 (97.3%)  0.451 –0.38
NSTEMI 1173 (40.0%) 778 (37.8%) 395 (45.2%) < 0.001 –2.01
  PCI within 24 h 1020/1173 (87.0%) 675/778 (86.8%) 345/395 (87.3%)  0.727 –0.18
Cardiogenic shock 117 (4.0%) 88 (4.3%) 29 (3.3%)  0.257 0.51
CPR on admission 113 (3.9%) 68 (3.3%) 45 (5.2%) 0.017 –1.02
Hypertension 1286 (43.9%) 853 (41.4%) 433 (49.6%) < 0.001 –2.19
Dyslipidemia 329 (11.2%) 239 (11.6%) 90 (10.3%)  0.308 0.49
Previous MI 70 (2.4%) 39 (1.9%) 31 (3.6%) 0.007 –1.02
Previous PCI 135 (4.6%) 78 (3.8%) 57 (6.5%)  0.001 –1.41
Previous CABG 5 (0.2%) 1 (0.0%) 4 (0.5%)  0.030 –0.83
Previous HF 22 (0.8%) 12 (0.6%) 10(1.1%)  0.157 –0.34
Previous CVA 139 (4.7%) 94 (4.6%) 45 (5.2%)  0.492 –0.30
Current smokers 1398 (47.7%) 1030 (50.0%) 368 (42.2%) < 0.001 2.06
Peak CK-MB [mg/dL] 142.8 ± 202.1 148.4 ± 217.1 129.5 ± 160.5  0.020 0.99
Peak troponin-I [ng/mL] 48.0 ± 117.8 49.1 ± 133.7 45.5 ± 66.6 0.451 0.34
NT-ProBNP [pg/mL] 1143.7 ± 2088.6 1069.6 ± 2024.4 1318.4 ± 2224.3  0.003 –1.17
hs-CRP [mg/dL] 8.8 ± 48.6 7.8 ± 32.6 11.4 ± 73.6 0.066 –0.63
Serum creatinine [mg/L] 1.01 ± 0.98 0.99 ± 0.82 1.05 ± 1.25  0.220 –0.57
eGFR [mL/min/1.73 m2] 90.2 ± 40.2 89.5 ± 36.7 91.8 ± 42.3  0.161 –0.58
Blood glucose [mg/dL] 146.0 ± 45.4 146.2 ± 44.5 145.6 ± 47.4 0.754 0.13
Hemoglobin A1c [%] 5.96 ± 0.21 5.95 ± 0.21 5.96 ± 0.22 0.426 –0.47
Total cholesterol [mg/dL] 190.5 ± 42.4 191.7 ± 42.6 187.7 ± 41.7 0.019 0.95
Triglyceride [mg/L] 136.3 ± 107.7 135.8 ± 105.1 137.4 ± 113.6 0.718 –0.15
HDL cholesterol [mg/L] 43.9 ± 15.4 44.1 ± 15.9 43.5 ± 14.0 0.341 0.40
LDL cholesterol [mg/L] 122.6 ± 48.0 122.4 ± 37.1 123.0 ± 67.0  0.781 –0.11
Discharge medications:
Acetylsalicylic acid 2918 (99.5%) 2048 (99.5%) 870 (99.7%) 0.494 –0.14
Clopidogrel 2513 (85.7%) 1797 (87.3%) 716 (82.0%) < 0.001 1.95
Ticagrelor 266 (9.1%) 162 (7.9%) 104 (11.9%) < 0.001 –1.71
   Prasugrel 137 (4.7%) 93 (4.5%) 44 (5.0%)  0.539 –0.25
Cilostazole 566 (19.3%) 406 (19.7%) 160 (18.3%)  0.383 0.45
   Beta-blockers 2591 (88.4%) 1849 (89.8%) 742 (85.0%) < 0.001 1.89
   CCBs 147 (5.0%) 88 (4.3%) 59 (6.8%)  0.005 –1.27
   Lipid lowering agent 2653 (90.5%) 1867 (90.7%) 786 (90.0%)  0.589 0.28
Angiographic and procedural characteristics
Infarct-related artery:
Left main 36 (1.2%) 17 (0.8%) 19 (2.2%)  0.002 –0.94
  Left anterior descending 1474 (50.2%) 1060 (51.5%) 414 (47.4%)  0.044 1.08
Left circumflex 494 (16.8%) 338 (16.4%) 156 (17.9%)  0.320 –0.51
Right coronary artery 928 (31.7%) 644 (31.3%) 284 (32.5%)  0.504 –0.34
Treated vessel:
Left main 72 (2.5%) 39 (1.9%) 33 (3.8%) 0.003 –1.14
  Left anterior descending 1753 (59.8%) 1249 (60.7%) 504 (57.7%)  0.139 0.80
Left circumflex 754 (25.7%) 511 (24.8%) 243 (27.8%)  0.087 –0.90
Right coronary artery 1114 (38.0%) 759 (36.9%) 355 (40.7%)  0.052 –1.04
ACC/AHA lesion type:
Type B1 398 (13.6%) 287 (13.9%) 111 (12.7%)  0.376 0.43
Type B2 958 (32.7%) 599 (29.1%) 359 (41.1%) < 0.001 –3.44
Type C 1288 (43.9%) 989 (48.0%) 299 (34.2%) < 0.001 3.65
Extent of coronary artery disease:
One-vessel 1547 (52.8%) 1058 (51.4%) 489 (56.0%)  0.019 –1.22
Two-vessel 897 (30.6%) 652 (31.7%) 245 (28.1%)  0.214 1.01
≥ Three-vessel 488 (16.6%) 349 (16.9%) 139 (15.9%)  0.494 0.34
Drug-eluting stents:
ZES 1006 (34.3%) 707 (34.3%) 299 (34.2%) 0.964 0.03
EES 1533 (52.3%) 1080 (52.5%) 453 (51.9%) 0.553 0.16
BES 393 (13.4%) 272 (13.2%) 121 (13.9%)  0.637 –0.25
IVUS 707 (24.1%) 494 (24.0%) 213 (24.4%)  0.814 –0.12
OCT 27 (0.9%) 23 (1.1%) 4 (0.5%)  0.094 0.39
FFR 38 (1.3%) 28 (1.4%) 10 (1.1%)  0.639 0.19
Stent diameter [mm] 3.15 ± 0.42 3.17 ± 0.42 3.12 ± 0.42  0.007 1.19
Stent length [mm] 26.8 ± 11.0 27.0 ± 10.9 26.2 ± 11.2  0.065 0.72
Number of stents 1.47 ± 0.78 1.46 ± 0.77 1.51 ± 0.81  0.136 –0.63
Values are mean ± standard deviations or number (%). The p values for continuous data obtained from analysis of the independent sample t-test. The p values for 
categorical data obtained from the chi-square test or Fisher’s exact test. 
ACC/AHA — American College of Cardiology/American Heart Association; ACEIs — angiotensin converting enzyme inhibitors; ARBs — angiotensin II type 1 receptor 
blockers; BES — biolimus-eluting stents; BMI — body mass index; CABG — coronary artery bypass graft; CCBs — calcium channel blockers; CK-MB — creatine 
kinase myocardial band; CPR — cardiopulmonary resuscitation; CVA — cerebrovascular accidents; DBP — diastolic blood pressure; EES — everolimus-eluting stents; 
eGFR — estimated glomerular filtration rate; FFR — fractional flow reserve; HDL — high-density lipoprotein; HF — heart failure; hs-CRP — high sensitivity-C-reactive
protein; IVUS — intravascular ultrasound; LDL — low-density lipoprotein; LVEF — left ventricular ejection fraction; MI — myocardial infarction; NSTEMI — non-
STEMI; NT-proBNP — N-terminal pro-B-type natriuretic peptide; OCT — optical coherence tomography; PCI — percutaneous coronary intervention; SBP — systolic 
blood pressure; SD — standardized mean difference; STEMI — ST-segment elevation myocardial infarction; ZES — zotarolimus-eluting stents 















POCO 133 (6.8) 57 (7.2) 0.695 1.064 (0.780–1.451) 0.695 1.020 (0.740–1.404) 0.906 1.105 (0.745–1.641) 0.619
All-cause death 37 (1.9) 22 (2.7) 0.158 1.459 (0.861–2.473) 0.161 1.394 (0.803–2.419) 0.238 1.025 (0.528–1.989) 0.941
Cardiac death 24 (1.2) 19 (2.3) 0.030 1.921 (1.052–3.507) 0.034 1.791 (0.952–3.371) 0.071 1.397 (0.642–3.042) 0.400
Re-MI 34 (1.7) 13 (1.7) 0.847 1.065 (0.562–2.018) 0.847 1.210 (0.626–2.340) 0.570 1.290 (0.544–3.062) 0.563
Death or MI 70 (3.6) 35 (4.4) 0.320 1.228 (0.818–1.843) 0.321 1.143 (0.751–1.741) 0.533 1.117 (0.661–1.889) 0.680
Any revascularization 69 (3.6) 24 (3.2) 0.569 1.144 (0.719–1.821) 0.569 1.150 (0.713–1.855) 0.568 1.140 (0.630–2.063) 0.666
ST (probable or definite) 11 (0.5) 3 (0.3) 0.495 1.554 (0.434–5.571) 0.498 1.736 (0.445–6.766) 0.427 3.003 (0.606–14.88) 0.178
aAdjusted by age, LVEF, STEMI, NSTEMI, CPR on admission, hypertension, current smokers, clopidogrel, ticagrelor, beta-blockers, ACC/AHA type B2 and C lesions
ACC/AHA — American College of Cardiology/American Heart Association; ACEIs — angiotensin converting enzyme inhibitors; ARBs — angiotensin II type 1 receptor blockers; CPR — cardiopulmonary 
resuscitation; HR — hazard ratio; CI — confidence interval; LVEF — left ventricular ejection fraction; MI — myocardial infarction; NSTEMI — non-STEMI; POCO — patient-oriented clinical outcome defined 
as a composite of all-cause death, Re-MI, or any repeat revascularization; Re-MI — recurrent myocardial infarction; ST — stent thrombosis; STEMI — ST-segment elevation myocardial infarction
Table 3. Independent predictors for patient-oriented composite outcome.
Variables
Unadjusted Adjusted
HR (95% CI) P HR (95% CI) P
ACEIs vs. ARBs 1.064 (0.780–1.451) 0.695 1.021 (0.745–1.399) 0.899
Age, ≥ 65 years 1.559 (1.171–2.075) 0.002 1.396 (1.015–1.919) 0.040
Male 1.314 (0.958–1.801) 0.090 1.161 (0.818–1.649) 0.402
LVEF, < 40% 1.436 (0.943–2.186) 0.092  1.309 (0.842–2.035) 0.231  
eGFR, < 60 mL/min/1.73m2 1.320 (0.903–1.931) 0.152 1.168 (0.784–1.740) 0.444
STEMI 1.308 (0.983–1.740) 0.065 1.299 (0.963–1.751) 0.087
Hypertension 1.039 (0.780–1.383) 0.795 1.118 (0.828–1.509) 0.468
Previous PCI 1.048 (0.537–2.047) 0.897 1.145 (0.581–2.258) 0.695
Cardiogenic shock 1.349 (0.714–2.551) 0.357 1.143 (0.590–2.212) 0.693
CPR on admission 2.435 (1.459–4.064) 0.001 2.418 (1.414–4.137) 0.001
LAD-IRA 1.031 (0.775–1.370) 0.836 1.055 (0.783–1.421) 0.727
Multivessel disease 1.719 (1.283–2.302) < 0.001 1.656 (1.226–2.238) 0.001
ACC/AHA type B2/C lesion 1.159 (0.841–1.598) 0.367 1.222 (0.881–1.695) 0.230
Stent diameter, < 3.0 mm 1.114 (0.814–1.524) 0.500 1.034 (0.749–1.427) 0.841
Stent length, ≥ 28 mm 1.150 (0.863–1.533) 0.341 1.066 (0.794–1.432) 0.669
ACC/AHA — American College of Cardiology/American Heart Association; ACEIs — angiotensin converting enzyme inhibitors; ARBs — angiotensin II type 1 receptor 
blockers; CI — confidence interval; CPR — cardiopulmonary resuscitation; eGFR — estimated glomerular filtration rate; HR — hazard ratio; IRA — infarct-related 
artery; LAD — left anterior descending coronary artery; PCI — percutaneous coronary intervention; POCO — patient-oriented clinical outcome defined as a composite of
all-cause death, Re-MI, or any repeat revascularization; STEMI — ST-segment elevation myocardial infarction





